Skip to main content
. Author manuscript; available in PMC: 2025 Feb 1.
Published in final edited form as: Curr Opin Biotechnol. 2023 Dec 16;85:103046. doi: 10.1016/j.copbio.2023.103046

Table 2.

Biomimetic protein corona-based organ-targeting strategies.

Target organs Biomimetic Approach Type of nanoparticles Proteins Mechanisms Ref.
Brain
Biomolecule modification LipNPs Apo A1, E, J Lipoprotein-medicated endocytosis [82]
Biomolecule modification LipNPs Apo E Lipoprotein-medicated endocytosis [83]
Biomolecule modification PTX/Aβ-CN-PMs Apo E Lipoprotein-medicated endocytosis [26]
Lung
Endogenous protein coating LNPs Albumin, fibrinogen Caveolae-medicated endocytosis [31]
Endogenous protein coating LNPs ApoE, β2-GPI, or Vtn Caveolae-medicated endocytosis [84]
Liver
Biomolecule modification RcP-NPs RBP4 RBP receptor-medicated uptake [89]
Biomolecule modification DNA tetrahedron Lipoproteins Lipoprotein-medicated endocytosis [85]
Spleen
Endogenous protein coating LNP Apo H Opsonization/spleen-targeted delivery via phagocytosis [84,86]
Endogenous protein coating LNP Apo E, Fg, C3 Opsonization/spleen-targeted delivery via phagocytosis [33,87]
Cell membrane decoration DEX-NPs C3b Opsonization/spleen-targeted delivery via phagocytosis [88]

Note: Apo, apolipoprotein; Tf, Transferrin; LNPs, lipid nanoparticles; LipNPs, Liposomal nanoparticles; AuNPs, gold nanoparticles; RcP, Retinol-conjugated polyetherimine; RBP, Retinol binding protein; Fg, fibrinogen; C3, complement 3; DEX-NPs, dextran-coated ferrous nanoparticles.